Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-8769
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHanisch, Daniela-
dc.contributor.authorKrumm, Andrea-
dc.contributor.authorDiehl, Tamara-
dc.contributor.authorStork, Carla M.-
dc.contributor.authorDejung, Mario-
dc.contributor.authorButter, Falk-
dc.contributor.authorKim, Ella-
dc.contributor.authorBrenner, Walburgis-
dc.contributor.authorFritz, Gerhard-
dc.contributor.authorHofmann, Thomas G.-
dc.contributor.authorRoos, Wynand P.-
dc.date.accessioned2023-02-07T08:03:54Z-
dc.date.available2023-02-07T08:03:54Z-
dc.date.issued2022-
dc.identifier.urihttps://openscience.ub.uni-mainz.de/handle/20.500.12030/8785-
dc.description.abstractOverexpression of histone deacetylases (HDACs) in cancer commonly causes resistance to genotoxic-based therapies. Here, we report on the novel mechanism whereby overexpressed class I HDACs increase the resistance of glioblastoma cells to the SN1 methylating agent temozolomide (TMZ). The chemotherapeutic TMZ triggers the activation of the DNA damage response (DDR) in resistant glioma cells, leading to DNA lesion bypass and cellular survival. Mass spectrometry analysis revealed that the catalytic activity of class I HDACs stimulates the expression of the E3 ubiquitin ligase RAD18. Furthermore, the data showed that RAD18 is part of the O6-methylguanine-induced DDR as TMZ induces the formation of RAD18 foci at sites of DNA damage. Downregulation of RAD18 by HDAC inhibition prevented glioma cells from activating the DDR upon TMZ exposure. Lastly, RAD18 or O6-methylguanine-DNA methyltransferase (MGMT) overexpression abolished the sensitization effect of HDAC inhibition on TMZ-exposed glioma cells. Our study describes a mechanism whereby class I HDAC overexpression in glioma cells causes resistance to TMZ treatment. HDACs accomplish this by promoting the bypass of O6-methylguanine DNA lesions via enhancing RAD18 expression. It also provides a treatment option with HDAC inhibition to undermine this mechanism.en_GB
dc.description.sponsorshipGefördert durch die Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 491381577de
dc.language.isoengde
dc.rightsCC BY*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subject.ddc610 Medizinde_DE
dc.subject.ddc610 Medical sciencesen_GB
dc.titleClass I HDAC overexpression promotes temozolomide resistance in glioma cells by regulating RAD18 expressionen_GB
dc.typeZeitschriftenaufsatzde
dc.identifier.doihttp://doi.org/10.25358/openscience-8769-
jgu.type.dinitypearticleen_GB
jgu.type.versionPublished versionde
jgu.type.resourceTextde
jgu.organisation.departmentFB 04 Medizinde
jgu.organisation.number2700-
jgu.organisation.nameJohannes Gutenberg-Universität Mainz-
jgu.rights.accessrightsopenAccess-
jgu.journal.titleCell death & diseasede
jgu.journal.volume13de
jgu.pages.alternative293de
jgu.publisher.year2022-
jgu.publisher.nameNature Publishing Groupde
jgu.publisher.placeLondonde
jgu.publisher.issn2041-4889de
jgu.organisation.placeMainz-
jgu.subject.ddccode610de
jgu.publisher.doi10.1038/s41419-022-04751-7de
jgu.organisation.rorhttps://ror.org/023b0x485-
jgu.subject.dfgLebenswissenschaftende
Appears in collections:DFG-491381577-G

Files in This Item:
  File Description SizeFormat
Thumbnail
class_i_hdac_overexpression_p-20230207085341162.pdf3.82 MBAdobe PDFView/Open